List of Excipients in Branded Drug VANDAZOLE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Upsher-smith Laboratories LLC	VANDAZOLE	metronidazole	0245-0860	EDETATE DISODIUM
Upsher-smith Laboratories LLC	VANDAZOLE	metronidazole	0245-0860	HYPROMELLOSE
Upsher-smith Laboratories LLC	VANDAZOLE	metronidazole	0245-0860	METHYLPARABEN
Upsher-smith Laboratories LLC	VANDAZOLE	metronidazole	0245-0860	PROPYLENE GLYCOL
Upsher-smith Laboratories LLC	VANDAZOLE	metronidazole	0245-0860	PROPYLPARABEN

Vandazole Excipient Strategy and Commercial Opportunities for Metronidazole Vaginal Gel

Last updated: September 24, 2026

Vandazole is a 0.75% metronidazole vaginal gel indicated for bacterial vaginosis. Its commercial opportunity is primarily formulation-led rather than molecule-led. The current excipient system is conventional: a carbomer gel using propylene glycol, methylparaben, edetate disodium, sodium hydroxide and purified water. Differentiation could come from preservative-free packaging, improved vaginal retention, reduced leakage, microbiome-conscious excipients, lower applicator waste and alternative delivery formats. [1]

What is Vandazole and how is it regulated?

Vandazole contains metronidazole at a concentration of 0.75% for intravaginal administration. A 5-gram dose delivers approximately 37.5 mg of metronidazole. The product is regulated as a prescription drug and is approved for the treatment of bacterial vaginosis in adult women. [1]

Attribute	Vandazole
Active ingredient	Metronidazole
Dosage form	Vaginal gel
Strength	0.75%
Route	Intravaginal
Typical dose	5 g intravaginally once daily for five days
Dose of metronidazole	Approximately 37.5 mg per application
Therapeutic category	Anti-infective
Primary indication	Bacterial vaginosis
Regulatory pathway	FDA-approved prescription drug
Reference regulatory identifier	NDA 022020
Biosimilar exposure	None; Vandazole is a small-molecule drug
Main competitive risk	Generic metronidazole vaginal gel and alternative vaginal anti-infectives

The product competes in a market that includes generic metronidazole vaginal gel 0.75%, clindamycin vaginal products and oral or alternative vaginal therapies for bacterial vaginosis.

What excipients are used in Vandazole?

The labeled inactive ingredients are carbomer 934, edetate disodium, methylparaben, propylene glycol, purified water and sodium hydroxide. [1]

Excipient	Formulation function	Commercial and technical relevance
Carbomer 934	Gelling and viscosity control	Controls residence time, spreadability and dose delivery
Propylene glycol	Solvent, humectant and wetting aid	Can affect comfort, osmolarity and local tolerability
Methylparaben	Antimicrobial preservative	Supports multi-dose or tube stability but creates preservative-free positioning risk
Edetate disodium	Chelating agent	Improves preservative performance and may reduce metal-catalyzed degradation
Sodium hydroxide	pH adjustment and carbomer neutralization	Controls gel viscosity and metronidazole stability
Purified water	Vehicle	Determines aqueous phase, osmolality and microbial-control requirements

The excipient system is economically efficient and compatible with conventional semisolid manufacturing. It also creates several formulation constraints. Carbomer viscosity is sensitive to neutralization, ionic strength and mixing conditions. Methylparaben can create consumer and prescriber interest in preservative-free alternatives. Propylene glycol can influence burning, irritation and osmolality in a sensitive mucosal environment.

How strong is the current excipient platform?

The current platform is strong for manufacturing simplicity and weak for product differentiation.

Manufacturing advantages

Carbomer-based aqueous gels are established pharmaceutical dosage forms. The process generally involves:

1. Hydration and dispersion of the carbomer.
2. Dissolution of metronidazole and soluble excipients.
3. Combination under controlled mixing.
4. pH adjustment with sodium hydroxide.
5. Deaeration, filling and packaging.

The process uses common equipment and does not require complex drug-device integration. This supports contract manufacturing and line extension development.

Technical limitations

The same formulation architecture can be reproduced by generic manufacturers. Carbomer, propylene glycol, methylparaben and edetate disodium are widely available excipients. These ingredients are unlikely to create meaningful freedom-to-operate barriers by themselves.

The principal technical risks are:

• Viscosity drift during storage.
• Inadequate carbomer hydration.
• Air entrapment during mixing.
• pH-related changes in gel structure.
• Preservative partitioning or reduced antimicrobial activity.
• Local irritation from preservative or solvent exposure.
• Leakage after administration.
• Dose variability from incomplete applicator emptying.

A reformulation can create a stronger commercial position only if it improves a measurable product attribute, such as retention, tolerability, ease of administration or adherence.

What excipient strategies could improve Vandazole?

1. Preservative-free vaginal gel

Removing methylparaben is the most direct reformulation opportunity. A preservative-free product would require a suitable container-closure system and validated microbial-control strategy.

Possible approaches include:

• Single-dose applicators.
• Unit-dose tubes.
• Blow-fill-seal packaging.
• Sterile or low-bioburden manufacturing.
• Reduced-use packaging that limits repeated container entry.

The commercial benefit would be a cleaner label and potential positioning for patients concerned about parabens or local irritation. The cost would be higher packaging expense and a more demanding microbial-control program.

A preservative-free product should not rely on the absence of methylparaben alone as a market claim. The development program would need to establish stability, microbiological quality, container integrity, dose uniformity and local tolerability.

2. Bioadhesive gel systems

A higher-retention gel could reduce leakage and improve perceived effectiveness. Carbomer already contributes viscosity, but a differentiated platform could use a combination of polymers such as polycarbophil, hydroxypropyl methylcellulose, hydroxyethylcellulose or selected mucoadhesive polymers.

The development objective would be controlled adhesion without excessive residue or difficult cleanup. Excessive viscosity can reduce patient acceptability and interfere with applicator performance.

A bioadhesive formulation could support:

• Lower leakage after administration.
• Longer vaginal residence.
• More consistent local exposure.
• A potential once-daily adherence advantage.
• Product claims based on administration experience rather than a new active ingredient.

Any claim of superior retention or reduced dosing frequency would require clinical support. A formulation patent could protect polymer ratios, pH, rheology, osmolality, packaging and release characteristics.

3. Lower-osmolality formulations

Vaginal products with high osmolality may cause discomfort and alter the local environment. A reformulation could reduce the contribution of propylene glycol or replace it with a less irritating solvent and humectant system.

Candidate changes include:

• Lower propylene glycol concentration.
• Glycerol or other polyol systems, subject to compatibility and tolerability testing.
• Optimized buffer capacity.
• Reduced total dissolved solids.
• A rheology system that maintains viscosity without excessive solvent loading.

This strategy is commercially relevant because tolerability can affect treatment completion and repeat prescribing. The key risk is that solvent changes can affect metronidazole solubility, preservative performance, viscosity and stability.

4. Microbiome-conscious excipient selection

Bacterial vaginosis involves disruption of the vaginal microbial environment. A formulation positioned around microbiome compatibility could attract interest, but claims must remain within the supported regulatory framework.

Potential development concepts include:

• Lower-irritation excipients.
• Reduced exposure to preservatives.
• Limited use of excipients that significantly disturb vaginal pH.
• Combination development with a probiotic or microbiome-supportive component, subject to a separate regulatory strategy.

A simple metronidazole reformulation would not establish a microbiome benefit without clinical evidence. The strongest near-term opportunity is a tolerability-focused product with measured effects on vaginal pH, symptoms and recurrence.

5. Alternative dose-delivery systems

The applicator is part of the product experience and can support differentiation. Opportunities include:

• Pre-filled single-dose applicators.
• Smaller-volume, higher-concentration gels.
• Tampon-like or insert-based delivery.
• Vaginal tablets or ovules.
• Metered-dose devices.
• Packaging with reduced residual volume.

A smaller-volume gel could reduce leakage and packaging material. However, increasing concentration may alter solubility, local exposure and irritation. A tablet or ovule would require a new dosage-form development program and could face different dissolution and retention challenges.

What formulation patents could protect a Vandazole line extension?

The strongest intellectual-property strategy would protect a complete product architecture rather than an individual excipient.

Potential claim categories include:

Patent category	Example protected subject matter	Expected strength
Composition	Metronidazole with defined polymer, solvent and pH ranges	Moderate if ranges are narrow and technically supported
Rheology	Defined viscosity, yield stress or shear-thinning profile	Moderate, but enforceability depends on reliable testing
Bioadhesion	Polymer combinations and residence-time performance	Moderate to strong if linked to reproducible formulation parameters
Preservative-free system	Single-dose package plus microbiological-control method	Moderate
Container closure	Applicator geometry, residual-dose reduction or dose metering	Moderate
Manufacturing process	Mixing order, hydration conditions, deaeration or neutralization sequence	Moderate if process is difficult to reproduce
Method of use	Reduced leakage, improved adherence or administration benefits	Variable and often dependent on clinical evidence
Combination therapy	Metronidazole with another anti-infective or microbiome component	Potentially strong, but requires new clinical and regulatory work

A patent directed only to the use of carbomer, propylene glycol or methylparaben would face substantial prior-art risk. A more defensible portfolio would combine composition claims with performance limits and packaging claims.

What is the patent and Orange Book position for Vandazole?

Vandazole is a small-molecule prescription product, so biosimilar law does not apply. Generic competition is governed by the abbreviated new drug application pathway and, where applicable, Orange Book patent certifications.

The commercial patent analysis should distinguish among:

• Patents listed for the approved product in the Orange Book.
• Unlisted formulation or manufacturing patents.
• Method-of-use patents.
• Patents covering later line extensions.
• Regulatory exclusivity separate from patent term.

A generic applicant may challenge listed patents through a Paragraph IV certification. The reference sponsor can then bring patent litigation within the statutory period, potentially triggering a 30-month stay of approval under the Hatch-Waxman framework. [2]

No reliable business conclusion should treat a formulation patent as a barrier unless the patent is listed, enforceable, relevant to the proposed generic product and unexpired in the target market.

When does Vandazole lose exclusivity?

Vandazole does not have biologic exclusivity and is exposed to generic substitution through the ANDA pathway. The practical loss-of-exclusivity date depends on the approved product’s listed patents, regulatory exclusivity, litigation outcomes and the timing of generic approvals.

For business planning, the relevant scenarios are:

Scenario	Commercial effect
No blocking patent or exclusivity	Generic entry can occur after FDA approval
Paragraph IV challenge with litigation	Entry may be delayed by litigation or settlement
Paragraph III certification	Generic approval waits until the relevant patent expiration
Non-infringement or invalidity finding	Early generic entry becomes possible
Authorized generic launch	Price erosion may occur before independent generic entry
Formulation line extension	New product may receive separate protection, but the active ingredient remains exposed

Patent expiration should be confirmed from current FDA Orange Book records and patent documents before valuation, licensing or litigation decisions. The active ingredient, metronidazole, is long established and does not provide meaningful composition-of-matter protection for Vandazole.

Which companies challenge metronidazole vaginal gel?

The principal competitive threat comes from generic manufacturers with approved or pending ANDAs for metronidazole vaginal gel 0.75%. The market can also include manufacturers of:

• Generic clindamycin vaginal cream.
• Clindamycin ovules.
• Oral metronidazole.
• Secnidazole oral granules.
• Other prescription products indicated for bacterial vaginosis.

Generic metronidazole gel is likely to compete primarily on price and pharmacy substitution. A differentiated Vandazole successor would need to compete on administration, tolerability, packaging or adherence rather than active-ingredient efficacy alone.

How does Vandazole compare with competing vaginal anti-infectives?

Product class	Active ingredient	Main commercial advantage	Main limitation
Vandazole and generic vaginal gel	Metronidazole	Established vaginal therapy and familiar dosing	Generic price pressure and leakage concerns
Clindamycin vaginal cream	Clindamycin	Established alternative therapy	Oil-based formulations may affect latex products and patient preference
Clindamycin ovule	Clindamycin	Alternative dosage form	Different administration experience and product-specific precautions
Oral metronidazole	Metronidazole	Low cost and simple systemic dosing	Greater systemic exposure and gastrointestinal or neurologic adverse-effect concerns
Secnidazole oral granules	Secnidazole	Single-dose oral treatment	Higher product cost and oral rather than local delivery

A vaginal formulation can be commercially differentiated by limiting systemic exposure and improving local administration. The product must still demonstrate acceptable tolerability and adherence.

What licensing opportunities exist for Vandazole excipients?

Licensing opportunities are more likely to involve formulation platforms, delivery devices or packaging than individual commodity excipients.

Attractive licensing targets include:

• Mucoadhesive polymer systems.
• Preservative-free semisolid platforms.
• Low-osmolality vaginal formulations.
• Single-dose applicator technology.
• Reduced-residual-volume packaging.
• Manufacturing processes that improve viscosity uniformity.
• Combination products with a separately regulated microbiome-supportive component.

A license should be structured around measurable performance rights, territorial coverage, development milestones and ownership of improvements. Commodity excipient supply agreements should include dual sourcing, change-control provisions, pharmacopeial compliance and interruption contingencies.

What geographic markets offer the best opportunity?

The United States offers the clearest Hatch-Waxman and Orange Book framework but also has strong generic price pressure. European markets may offer opportunities for device-led or tolerability-led products, although national reimbursement and prescription practices vary. Emerging markets may favor lower-cost generic presentations, while premium preservative-free or prefilled products face reimbursement constraints.

A geographic strategy should separate:

• U.S. prescription and pharmacy-substitution markets.
• European national reimbursement markets.
• Private-pay markets where convenience supports premium pricing.
• Markets with limited access to vaginal dosage forms.
• Markets where oral metronidazole remains dominant.

The same excipient strategy may not support the same commercial positioning across regions. A preservative-free unit-dose product may command a premium in private-pay channels but require substantial health-economic evidence in reimbursed systems.

What generic launch risks exist for a reformulated Vandazole product?

A reformulation does not eliminate generic risk. A generic applicant may design around a new formulation patent by using:

• A different carbomer grade.
• A different preservative system.
• A non-equivalent applicator.
• A different polymer combination.
• A comparable viscosity profile outside the claimed range.
• A different manufacturing process.

The most defensible strategy is to combine patent protection with regulatory differentiation and product experience. Packaging, dose metering and clinically demonstrated tolerability can be harder to copy than a conventional excipient recipe.

Key Takeaways

• Vandazole is a 0.75% metronidazole vaginal gel for bacterial vaginosis.
• Its labeled excipients are carbomer 934, propylene glycol, methylparaben, edetate disodium, sodium hydroxide and purified water.
• The current excipient system supports low-cost manufacturing but offers limited standalone patent protection.
• The strongest reformulation opportunities are preservative-free packaging, improved mucoadhesion, lower osmolality, reduced leakage and better dose delivery.
• A new formulation should be protected through composition, rheology, packaging, manufacturing and method-of-use claims.
• Generic metronidazole vaginal gel is the primary commercial threat.
• Vandazole has no biosimilar risk because metronidazole is a small molecule.
• Current Orange Book listings, patent expiration dates, Paragraph IV filings and litigation outcomes must control any exclusivity valuation.
• Commercial value will depend more on measurable patient-experience improvements than on substitution of one common excipient for another.

FAQs About Vandazole Excipient Strategy

Can methylparaben be removed from Vandazole?

Yes. A preservative-free formulation could use single-dose packaging or a validated antimicrobial-control strategy. Removing methylparaben would require new stability, microbiological quality and container-closure data.

Is carbomer 934 a strong patent barrier for Vandazole?

No. Carbomer 934 is a widely used pharmaceutical excipient. Protection would need to arise from a specific polymer combination, concentration range, rheology profile, manufacturing process or delivery system.

Could Vandazole be reformulated into a vaginal tablet?

Yes, but a vaginal tablet would be a new dosage-form development program. Dissolution, local exposure, retention, irritation, packaging and clinical comparability would require evaluation.

Does Vandazole have biosimilar competition?

No. Vandazole contains metronidazole, a small-molecule active ingredient. Competition proceeds through generic drug pathways rather than biosimilar applications.

What is the most commercially attractive Vandazole line extension?

A preservative-free, prefilled, low-leakage vaginal gel with validated tolerability and convenient administration offers the clearest line-extension opportunity. Its value would depend on clinical differentiation, packaging economics and enforceable formulation or device protection.

References

1. U.S. National Library of Medicine. (n.d.). Vandazole- metronidazole gel: Prescribing information. DailyMed.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.